RxDoctor Payments Data

Roderick Kaufmann, MD

Dermatology · Princeton, NJNPI 1740245539

Payments from drug & device makers

$9,553in general payments, 2019–2025

Across 332 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$1K
  • AbbVie$1K
  • Johnson & Johnson$746
  • Regeneron Healthcare Solutions, Inc.$635
  • Galderma Laboratories, L.p.$594
  • Arcutis Biotherapeutics, Inc.$490
  • plus $5K from 29 others

What the payments were for

  • Food & beverage$9,06395%
  • Education$4915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,553 in reported general payments places this provider in the 80th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$527,147
Medicare patients
1,623
Services billed
6,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast33$167,380
Dupixent PenDupilumab35$132,272
Cosentyx Sensoready (2 Pens)Secukinumab12$111,699
Doxycycline Ir-DrDoxycycline Monohydrate16$15,270
Metronidazole105$5,506
Clobetasol Propionate91$4,757
Calcipotriene15$4,315
Ketoconazole241$4,001
Imiquimod188$3,649
Tretinoin48$3,528
Triamcinolone Acetonide288$2,533
Doxycycline Hyclate72$2,394
Gentamicin Sulfate44$1,826
Betamethasone Dipropionate49$1,679
Fluorouracil33$1,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$403$167,38033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →